(Q35669197)

9 August 2017

title

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study (English)

1 reference

9 August 2017

0 references

1 reference

11

Robert J Tibshirani

1 reference

9 August 2017

Dita Gratzinger

2

0 references

Ranjana H. Advani

12

object named as

Ranjana H Advani

1 reference

9 August 2017

15

Richard T Hoppe

1 reference

9 August 2017

Youn H Kim

1

1 reference

9 August 2017

Cameron Harrison

3

1 reference

9 August 2017

Joshua D Brody

4

1 reference

9 August 2017

Debra K Czerwinski

5

1 reference

9 August 2017

Weiyun Z Ai

6

1 reference

9 August 2017

Anjali Morales

7

1 reference

9 August 2017

Farah Abdulla

8

1 reference

9 August 2017

Leon Xing

9

1 reference

9 August 2017

Daniel Navi

10

1 reference

9 August 2017

Bharathi Lingala

13

1 reference

9 August 2017

Sumit Shah

14

1 reference

9 August 2017

Ronald Levy

16

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

9 August 2017

1 reference

9 August 2017

volume

119

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

355-363

1 reference

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Migration of skin dendritic cells in response to ionizing radiation exposure

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Mycosis fungoides and Sézary syndrome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Development of TLR9 agonists for cancer therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Calreticulin exposure dictates the immunogenicity of cancer cell death

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Combining radiotherapy and immunotherapy: a revived partnership

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Immunopathogenesis and therapy of cutaneous T cell lymphoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

WHO-EORTC classification for cutaneous lymphomas

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Mechanisms and functional significance of tumour-induced dendritic-cell defects

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257006

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself

25 September 2018

1 reference

12 December 2020

Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation

1 reference

12 December 2020

Transimmunization for cutaneous T cell lymphoma: a Phase I study

1 reference

12 December 2020

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

10.1182/BLOOD-2011-05-355222

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference